Humacyte (NASDAQ:HUMA – Get Free Report) and DBV Technologies (NASDAQ:DBVT – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.
Risk & Volatility
Humacyte has a beta of 2.64, suggesting that its stock price is 164% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.84, suggesting that its stock price is 184% less volatile than the S&P 500.
Institutional & Insider Ownership
44.7% of Humacyte shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 3.1% of Humacyte shares are held by insiders. Comparatively, 1.1% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Humacyte | -3,955.05% | -612.88% | -80.03% |
| DBV Technologies | -5,392.17% | -120.95% | -88.35% |
Analyst Ratings
This is a breakdown of current ratings for Humacyte and DBV Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Humacyte | 1 | 1 | 6 | 0 | 2.62 |
| DBV Technologies | 1 | 0 | 5 | 0 | 2.67 |
Humacyte currently has a consensus price target of $4.48, suggesting a potential upside of 702.52%. DBV Technologies has a consensus price target of $45.25, suggesting a potential upside of 310.62%. Given Humacyte’s higher possible upside, research analysts clearly believe Humacyte is more favorable than DBV Technologies.
Earnings & Valuation
This table compares Humacyte and DBV Technologies”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Humacyte | $2.04 million | 76.04 | -$40.83 million | ($0.44) | -1.27 |
| DBV Technologies | N/A | N/A | -$146.95 million | ($3.01) | -3.66 |
Humacyte has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.
Summary
Humacyte beats DBV Technologies on 10 of the 13 factors compared between the two stocks.
About Humacyte
Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. Founded in France, the company’s research centers on epicutaneous immunotherapy, an approach that delivers small amounts of an allergen through the skin using a patch. Its lead investigational program is Viaskin Peanut, a patch-based treatment being developed for peanut allergy. DBV has also conducted research into treatments for other conditions, including milk allergy and eosinophilic esophagitis.
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
